For melanoma treated with BRAF inhibitors, resistance generally occurs within the first year and usually involves reactivation of the MAPK pathway by the acquisition of secondary NRAS or MEK mutations or alternative splicing or amplification of the BRAF gene itself [52]. Here, NRAS is linked to melanoma.